Bristol Myers Squibb announced the COMMANDS study, a Phase III, open-label, randomized trial evaluating Reblozyl(luspatercept-aamt), met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in red blood cell transfusion independence (RBC-TI) with concurrent hemoglobin (Hb) increase in the first-line treatment of adult patients with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) who require RBC transfusions
Cerus Corporation announced that its European Phase III clinical trial of red blood cells treated with the Intercept Blood System...
Bristol-Myers Squibb Company and Acceleron Pharma announced data evaluating the erythroid maturation agent (EMA) Reblozyl (luspatercept-aamt) in patients with anemia...
Bristol Myers Squibb announced first results from the Phase III COMMANDS study, an open-label, randomized trial evaluating Reblozyl (luspatercept-aamt) versus epoetin alfa, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia in adult patients with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) who require red blood cell (RBC) transfusions and are ESA-naïve. Results from the study will be featured at the American Society of Clinical Oncology (ASCO) Annual Meeting and in an oral presentation of select abstracts during a plenary session at the European Hematology Association (EHA) Congress.
Bristol Myers Squibb Canada and Acceleron Pharma Inc. announced that Health Canada has approved Reblozyl (luspatercept for injection) for the treatment of adult patients with transfusion-dependent anemia requiring at least two RBC red blood cell (RBC) units over 8 weeks resulting from very low-to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.
Celgene Corporation and Acceleron Pharma Inc. announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid...
Bristol Myers Squibb announced updated results from the primary analysis of the Phase III COMMANDS trial, comparing Reblozyl) (luspatercept-aamt versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS) (Oral Presentation #193) who may require red blood cell (RBC) transfusions.
Celgene Corporation and Acceleron Pharma Inc. announced the FDA has approved Reblozyl (luspatercept-aamt) for the treatment of anemia in adult...
bluebird bio, Inc. announced the FDA has approved Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions.